Small molecule kinase inhibitor library

The purchase of a library of many drug candidates, called a small molecule kinase inhibitor library allows the potential for new cancer drug development.

There are many ongoing mechanisms in a cell that prevents it from turning cancerous. Kinases are essential proteins involved in anti-cancer mechanisms. Kinases are enzymes as they have biological activity. The root of many cancers such as chronic myeloid leukaemia, melanoma and a large proportion of non-small cell lung cancers are due to mutations of these proteins.

Targetting kinases in cancer treatment

Drugs that inhibit the effects of mutant kinases have proven to be very effective. These drugs are called kinase inhibitors. Many hundreds of kinase inhibitors have been developed and over twenty of them are now used in cancer treatment. These drugs can also be used as starting points for the development of new inhibitors.

Funding from Hope Against Cancer has allowed the Leicester Cancer Research Centre to purchase a library of 356 kinase inhibitors. This central resource is available to cancer researchers based in Leicester. These kinase inhibitors can be tested to identify good candidates to be developed into new cancer drugs, or be used in combination with other drugs.

This award of £9,300 was awarded to Prof Richard Bayliss at the Department of Cancer Studies and Molecular Medicine and Biochemistry at the University of Leicester and is part of Hope’s funding of priority research in the new Leicester Centre of Excellence.

More information (links open in a new tab):

Protein kinase inhibitors (1)

Protein kinase inhibitors (2)